11:25 AM EDT, 09/02/2025 (MT Newswires) -- (Updates to include Arrowhead's stock movement in the headline and the first paragraph.)

Arrowhead Pharmaceuticals ( ARWR ) shares rose 9.2% in recent Tuesday trading after the company announced a global licensing and collaboration agreement for its ARO-SNCA preclinical stage siRNA therapy to treat synucleinopathies, including Parkinson's disease, with Novartis ( NVS ) .

Upon closing, Arrowhead will receive a $200 million upfront payment with eligibility for up to $2 billion in potential milestone payments and royalties on commercial sales.

The agreement also includes other collaboration targets that utilize Arrowhead's targeted RNAi Molecule platform, the company said.

Novartis ( NVS ) shares fell 0.4%.

Price: 24.07, Change: +2.04, Percent Change: +9.24